002728 Teyi Pharmaceutical Group
- 9.57
- -0.20-2.05%
Teyi Pharmaceutical Group News
Teyi Pharmaceutical (002728.SZ): The company has not yet carried out any business related to synthetic organisms
Gelonghui, May 9 | Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that the company has not yet carried out any business related to synthetic organisms.
Teyi Pharmaceutical (002728.SZ): The company's inventory mainly includes raw materials, in-process products, finished products and low-value consumables
Gelonghui, May 9丨Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that the company's inventory mainly includes raw materials, in-process products, finished products, and low-value consumables. In terms of procurement, the company generally formulates raw material procurement plans based on market demand and raw material supply and demand, and implements economical batch purchases to control procurement costs, thereby reducing the company's operating costs. Furthermore, due to the gradual increase in the company's sales share and variety of proprietary Chinese medicinal products, the Chinese herbal medicines that the company needs to reserve have also increased accordingly. All of these will result in an increase in the company's material inventory. In terms of product inventory, the company will comprehensively consider market environment factors
Special Pharmaceutical (002728.SZ): One of the Chinese herbal medicines used in cough medicine tablets is simply an extract extracted from poppy shell. Poppy shell is a nationally controlled medicinal herb, priced by the National Development and Reform Co
Gelonghui, April 24 | Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that one of the Chinese herbal medicines used in the company's cough medicine is simply an extract extracted from poppy shells. Poppy shell is a nationally controlled medicinal herb, and the price is set by the National Development and Reform Commission. In addition, the other raw materials needed for cough medicine tablets, such as aster, orange red, bellflower, citrus aurantium, and 100 parts, are all common Chinese herbal medicines on the market. The market supply is large, and there is no supply pressure. In addition, the company is equipped with a special warehouse for Chinese herbal medicines, so the company can make sufficient safe reserves according to subsequent market needs. Judging from the current level of consumption of Cough Remedies, Cough Remedies every day
Teyi Pharmaceutical (002728.SZ): The company holds approvals for drugs such as Qianbai rhinitis tablets, etc., and is currently not producing
On April 24, Gelonghui Pharmaceutical (002728.SZ) said on the investor interactive platform that the company holds pharmaceutical approvals for ketotifen fumarate tablets, chlorphenamine maleate tablets, nasal comfort tablets, and Qianbai rhinitis tablets, and are currently not producing them.
Teyi Pharmaceutical (002728.SZ): Net profit of 9.1546 million yuan in the first quarter decreased by 91.32% year on year
On April 19, Ge Longhui Pharmaceutical (002728.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 165 million yuan, down 45.88% year on year; net profit attributable to shareholders of listed companies was 9.1546 million yuan, down 91.32% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 8.924,600 yuan, down 91.51% year on year; basic earnings per share were 0.03 yuan.
We Wouldn't Be Too Quick To Buy Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) Before It Goes Ex-Dividend
Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one business day before the record date, which is the cut-off date for sharehold
Zhitong A Share Sale Restriction and Release List | April 11
According to the Zhitong Finance App, the ban on restricted shares of 9 listed companies was lifted on April 11, with a total market value of about 4.454 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Sinoma International 600970, share incentives, 15.3612 million, Teyi Pharmaceutical 002728, original shareholder placement and listing 2014.65 million Xingyuan Material 300568 share incentives limited sale and circulation of 1,5309 million Huichuangda 300909 additional A-shares, corporate placement and listing of 1,50312 Wan Jiangyan Group 601065 shares restricted circulation before issuance
Teyi Pharmaceutical (002728.SZ): The ban on 2014.65 million restricted shares will be lifted on April 11
Gelonghui, April 8, 丨 Teyi Pharmaceutical (002728.SZ) announced an indicative announcement on the issuance of restricted shares to specific targets in 2023. The number of restricted shares lifted this time is 201465.14 million shares, accounting for 5.5235% of the company's total share capital at present. The current limited-sale stock listing circulation date is April 11, 2024 (Thursday).
Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) Surges 7.2%; Retail Investors Who Own 54% Shares Profited Along With Insiders
Key Insights The considerable ownership by retail investors in Teyi Pharmaceutical GroupLtd indicates that they collectively have a greater say in management and business strategy The top 25 shareho
Teyi Pharmaceutical (002728.SZ): Currently there is no planting base for Chinese herbal medicines
Gelonghui, March 22丨Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that all Chinese herbal medicines required by the company to produce proprietary Chinese medicines are purchased from outside, and there is currently no Chinese herbal medicine cultivation base.
Teyi Pharmaceutical (002728.SZ): No research or plans on weight loss drugs
Gelonghui March 22丨Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that the company has no research or plans on diet pills yet.
Teyi Pharmaceutical GroupLtd (SZSE:002728) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) just reported some strong earnings, and the market reacted accordingly with a healthy uplift in the share price. However, our analysis suggests that sh
Teyi Pharmaceutical (002728.SZ): Cardiovascular products mainly include blood clotong dispersible tablets, Yixinshu granules, ginkgo biloba dispersible tablets, captopril tablets, etc.
On March 11, Gelonghui Pharmaceutical (002728.SZ) said on the investor interactive platform that the company has a wide range of pharmaceuticals. The main cardiovascular products include blood clotting dispersible tablets, Yixinshu granules, ginkgo biloba dispersible tablets, and captopril tablets. The company has always attached importance to investment in R&D, and regards R&D as the driving force for enterprise development. In the later stages, it will continue to increase R&D and innovation efforts according to R&D and market demand. The company's R&D focus is mainly on proprietary Chinese medicines: first, continue to promote some innovative traditional Chinese medicine drugs and improved new drugs to achieve marketing and sales goals as soon as possible; second, through clinical research or real-world research, on characteristics
Gelonghui Announcement Selection | Huarong Chemical: Net profit increased by 13.53% to 139 million yuan in 2023, and plans to pay 10 to 2 yuan; Shanghai Industrial: Satellite components-related business and robot system integration business account for re
[Hot Focus] Shanghai Shanghai Industrial (603131.SH): The satellite component-related business and robot system integration business account for a relatively small share of the revenue. Currently, the company's main business has not changed. Shanghai Shanghaihang Satellite Technology Co., Ltd., a wholly-owned subsidiary of the company, is involved in some satellite component-related businesses, and its revenue accounts for about 1%-2% of the listed companies' revenue; the company is involved in robot system integration, and the revenue accounts for about 1%-2% of the listed company's revenue. 603131.SH Satellite component-related business and robot system integration business account for relatively small revenue
Teyi Pharmaceutical (002728.SZ): Net profit increased by 42.07% to 253 million yuan in 2023, plans to convert 10 to 4 to 5 yuan
Gelonghui, March 7 | Teyi Pharmaceutical (002728.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,067 million yuan, an increase of 20.38%; achieved net profit attributable to shareholders of listed companies of 253 million yuan, an increase of 42.07% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 249 million yuan, an increase of 43.61% year on year; basic income per share is 0.77 yuan; it plans to distribute cash dividends of 5.00 yuan (tax included) to all shareholders for every 10 shares, using capital reserves to the whole Shareholders added 4 shares for every 10 shares.
Improved Earnings Required Before Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) Stock's 29% Jump Looks Justified
Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) shareholders are no doubt pleased to see that the share price has bounced 29% in the last month, although it is still struggling to make up recently los
Teyi Pharmaceutical GroupLtd (SZSE:002728) Stock Performs Better Than Its Underlying Earnings Growth Over Last Three Years
While Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 25% in the last quart
Teyi Pharmaceutical (002728.SZ): The drug ibuprofen tablets passed the consistency evaluation
On February 19, Gelonghui Pharmaceutical (002728.SZ) announced that the company recently obtained the “Drug Supplement Application Approval Notice” for “ibuprofen tablets” approved and issued by the State Drug Administration. After review, the above drugs passed the consistent evaluation of the quality and efficacy of chemical generic drugs. The ibuprofen tablets that passed the one-time evaluation this time have a total of 2 specifications, 0.1 g and 0.2 g, respectively (of which 0.2 g is a new specification). Ibuprofen tablets are used to relieve mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, and dysmenorrhea. It is also used for fever caused by the common cold or influenza.
Teyi Pharmaceutical GroupLtd (SZSE:002728) Has A Rock Solid Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, whe
Special Pharmaceutical (002728.SZ): Drugs cover categories such as cough relief, antipyretic, antibiotics, antiviral drugs, digestive system, etc.
Gelonghui, Feb. 6 | Special Pharmaceutical (002728.SZ) said on the investor interactive platform that influenza patients mainly showed fever, often with respiratory symptoms such as cough, sore throat, nasal congestion, and runny nose. It was accompanied by general discomfort such as headache and muscle aches, and some experienced gastrointestinal discomfort. Looking at related symptoms, the company's drugs cover categories such as cough relief, fever relief, antibiotics, antiviral drugs, and digestive system. The company's core product, Cough Remedies, has a history of 100 years. It was famous in the late Qing Dynasty, and has the effect of “promoting lung expectoration, relieving cough and asthma”. In addition, the company's products are also small in terms of relieving cough and phlegm
Analysis
Price Target
No Data
